Sonolisib is an irreversible and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)).

Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K/Akt signaling pathway. It may cause inhibition of tumor cell growth and survival in susceptible tumor cell populations [3].

502632-66-8

C29H35NO8

525.59

PX-866

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years